NewsBenzingaT3 디펜스, 판매자로부터 킵존의 발행주식 및 미발행주식 전부를 인수하기 위한 수정안 D에 서명; 양측은 매매 계약을 수정하여 매매 가격을 1,539,800달러로 인상하기로 합의 T3 디펜스, 판매자로부터 킵존의 발행주식 및 미발행주식 전부를 인수하기 위한 수정안 D에 서명; 양측은 매매 계약을 수정하여 매매 가격을 1,539,800달러로 인상하기로 합의 Benzinga 2026.11.06 22:30 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'US Presses UN Agency Over Taiwan Flight Restrictions, China Hits Back' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen